Primary neuroendocrine tumors of the ovary: Management and outcomes

Abstract Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples. This retrospective study aimed to investi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Pang, Zhiqiang Guo
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	chemotherapy clinical behavior ovarian cancer ovarian neuroendocrine tumor SEER database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4e7bed3ec3234d74ada074377a0183da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e7bed3ec3234d74ada074377a0183da
record_format	dspace
spelling	oai:doaj.org-article:4e7bed3ec3234d74ada074377a0183da2021-12-01T04:49:16ZPrimary neuroendocrine tumors of the ovary: Management and outcomes2045-763410.1002/cam4.4368https://doaj.org/article/4e7bed3ec3234d74ada074377a0183da2021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4368https://doaj.org/toc/2045-7634Abstract Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples. This retrospective study aimed to investigate the clinical behavior of ovarian NETs. Methods The Surveillance, Epidemiology, and End Results database was used to identify women diagnosed with ovarian NETs from 2004 to 2015. Overall survival (OS), cancer‐specific survival (CSS), and independent prognostic factors for ovarian NETs were evaluated. The effects of different treatments on prognosis were also compared, as were OS and CSS rates for histological subtypes. Results The 5‐year OS rates were 83.3%, 30.0%, 20.3%, and 9.8% for patients in stages I (n = 159), II (n = 23), III (n = 101), and IV (n = 148), respectively. The 5‐year CSS rates were 85.6%, 41.7%, 21.2%, and 9.8% for patients in stages I–IV, respectively. Age, American Joint Committee on Cancer (AJCC) stage, lymph node metastasis, treatment, and histological type were related to poor OS and CSS. In the early stage, the 5‐year OS and CSS rates were 97.03% and 96.90%, respectively. For patients in the advanced stage receiving comprehensive treatment (surgery + chemotherapy + radiotherapy), the 5‐year OS and CSS rates were 72.9% and 70.00%, respectively. When comparing low‐ and high‐grade neuroendocrine carcinoma, 5‐year OS rates were 93.96% and 7.01%, 5‐year CSS rates were 97.44% and 7.31%, 10‐year OS rates were 93.56% and 2.34%, and 10‐year CSS rates were 97.44% and 4.88%, respectively. Conclusion Age, AJCC stage, treatment, and histological type are independent prognostic factors of ovarian NETs. OS and CSS are relatively good for early‐stage cases treated with surgery alone, whereas more comprehensive treatment is required to improve OS and CSS in the advanced stage.Li PangZhiqiang GuoWileyarticlechemotherapyclinical behaviorovarian cancerovarian neuroendocrine tumorSEER databaseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8558-8569 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemotherapy clinical behavior ovarian cancer ovarian neuroendocrine tumor SEER database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chemotherapy clinical behavior ovarian cancer ovarian neuroendocrine tumor SEER database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Li Pang Zhiqiang Guo Primary neuroendocrine tumors of the ovary: Management and outcomes
description	Abstract Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples. This retrospective study aimed to investigate the clinical behavior of ovarian NETs. Methods The Surveillance, Epidemiology, and End Results database was used to identify women diagnosed with ovarian NETs from 2004 to 2015. Overall survival (OS), cancer‐specific survival (CSS), and independent prognostic factors for ovarian NETs were evaluated. The effects of different treatments on prognosis were also compared, as were OS and CSS rates for histological subtypes. Results The 5‐year OS rates were 83.3%, 30.0%, 20.3%, and 9.8% for patients in stages I (n = 159), II (n = 23), III (n = 101), and IV (n = 148), respectively. The 5‐year CSS rates were 85.6%, 41.7%, 21.2%, and 9.8% for patients in stages I–IV, respectively. Age, American Joint Committee on Cancer (AJCC) stage, lymph node metastasis, treatment, and histological type were related to poor OS and CSS. In the early stage, the 5‐year OS and CSS rates were 97.03% and 96.90%, respectively. For patients in the advanced stage receiving comprehensive treatment (surgery + chemotherapy + radiotherapy), the 5‐year OS and CSS rates were 72.9% and 70.00%, respectively. When comparing low‐ and high‐grade neuroendocrine carcinoma, 5‐year OS rates were 93.96% and 7.01%, 5‐year CSS rates were 97.44% and 7.31%, 10‐year OS rates were 93.56% and 2.34%, and 10‐year CSS rates were 97.44% and 4.88%, respectively. Conclusion Age, AJCC stage, treatment, and histological type are independent prognostic factors of ovarian NETs. OS and CSS are relatively good for early‐stage cases treated with surgery alone, whereas more comprehensive treatment is required to improve OS and CSS in the advanced stage.
format	article
author	Li Pang Zhiqiang Guo
author_facet	Li Pang Zhiqiang Guo
author_sort	Li Pang
title	Primary neuroendocrine tumors of the ovary: Management and outcomes
title_short	Primary neuroendocrine tumors of the ovary: Management and outcomes
title_full	Primary neuroendocrine tumors of the ovary: Management and outcomes
title_fullStr	Primary neuroendocrine tumors of the ovary: Management and outcomes
title_full_unstemmed	Primary neuroendocrine tumors of the ovary: Management and outcomes
title_sort	primary neuroendocrine tumors of the ovary: management and outcomes
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/4e7bed3ec3234d74ada074377a0183da
work_keys_str_mv	AT lipang primaryneuroendocrinetumorsoftheovarymanagementandoutcomes AT zhiqiangguo primaryneuroendocrinetumorsoftheovarymanagementandoutcomes
_version_	1718405721742114816

Primary neuroendocrine tumors of the ovary: Management and outcomes

Ejemplares similares